Last week, the 5th U.S. Circuit Court of Appeals ruled that the federal government erred in approving abortion drugs and that it violated federal law by allowing the drugs to be shipped via mail. The decision left intact part of a Texas-based federal judge's ruling that ended the availability of mifepristone by mail and required that the drug be administered in the presence of a physician.
Those restrictions will not take effect right away; the Supreme Court previously intervened to keep the drug available during the legal fight.
Jim Harden of CompassCare Pregnancy Services maintains that the drugs should not have been approved so quickly.
"A new study shows that 1 in 10 women who start the chemical abortion process end up in the emergency room, and yet the abortion industry is calling it safer than Tylenol," he notes.
With the appeals court's ruling, Harden believes the abortion industry is shaking in their boots.
"They're scared to death because they know that this dangerous drug could never make it through the FDA's gold standard safety and efficacy process for approving drugs, which is why the FDA illegally approved it back in 2000 treating pregnancy like a disease," the pro-lifer recalls. "I'm not kidding you."
Harden agrees with other pro-lifers who believe the federal drug agency has become politicized, especially under the Biden administration.
"Approving this dangerous mifepristone drug, to the detriment of women and women's health, has demonstrated that they are willing to put politics over healthcare," Harden contends. "It's an eye-opener for some people, but it is a sad, sad reality; they're being treated like a presidential ping pong ball to do the bidding of a political narrative."
Harden's research suggests that if the restrictions remain in place, the lives of as many as 140,000 preborn babies will be saved annually.
